Medical News

RSS

Medisafe 1 Technologies, Natural Dream Laboratories enter distribution agreement

Medisafe 1 Technologies Corp., a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that the company has signed a distribution agreement with Natural Dream Laboratories Company Ltd for Medisafe 1 to carry a wide range of health related products in the Natural Dream laboratories Company product line.

12 Mar 2012

ESMO welcomes EC proposal to streamline access to medicines

The European Society for Medical Oncology (ESMO) welcomes the recent proposal by the European Commission aimed at streamlining the process and shortening the timeline surrounding national decisions on pricing drugs and reimbursement of payment made for medicines. This initiative, says ESMO, will facilitate patient access to innovative treatments on an EU-wide level.

12 Mar 2012

LensAR closes $24 million private financing

LensAR Inc., a developer of the next generation of laser systems for cataract surgery, announced the closing of a $24 million private financing which included investments from Aisling Capital and Florida Growth Fund (FGF).

12 Mar 2012

Over 71% of all rogue online pharmacies clustered with just ten Registrars

In the wake of news regarding counterfeit Avastin hitting the US market, a new analysis released by LegitScript.com estimates that out of roughly 450 companies with ICANN accreditations to sell domain names, over 71% of all rogue online pharmacies are clustered with just ten Registrars, with over 50% of all rogue online pharmacies at just two Registrars.

12 Mar 2012

Political cartoon: 'Aerodynamic Drag'

Kaiser Health News provides a fresh take on health policy developments with "Aerodynamic Drag" by Lisa Benson.

12 Mar 2012

AB SCIEX announces commercial expansion in Brazil

AB SCIEX, a global leader in life science analytical technologies, today announced its expansion of commercial operations in Brazil to support the Brazilian scientific community's increasing use of mass spectrometry for food safety testing, environmental analysis, academic research, drug development, forensic toxicology and clinical research.

12 Mar 2012

Allon advances into second phase of work in preclinical PD model

Allon Therapeutics Inc. announced today the completion of its first phase of work in a preclinical Parkinson's disease model and advancement into the second phase of work. Both phases are funded by The Michael J. Fox Foundation for Parkinson's Research and carried out by Prof. Marie-Francoise Chesselet's lab at the University of California Los Angeles.

12 Mar 2012

InflammaGen Therapeutics initiates Shok-Pak Phase 2 pilot study

InflammaGen Therapeutics, a development-stage, critical care company initially focused on the diagnosis, treatment and prevention of multi-organ failure (MOF), announced today that the Company has initiated a 200-patient Phase 2 pilot study to examine the efficacy and safety of InflammaGen Shok-Pak as a potential treatment for critically ill patients in the Intensive Care Unit.

12 Mar 2012

Thermo Fisher Scientific launches Acclaim Surfactant Plus and MAbPac SCX-10 chromatography columns

Thermo Fisher Scientific Inc., the world leader in serving science, today introduced new chromatography columns, the Thermo Scientific Acclaim Surfactant Plus and smaller-particle sized Thermo Scientific MAbPac SCX-10.

From Thermo Fisher Scientific Inc. 12 Mar 2012

Former 'legal high' even more popular after UK ban

The former 'legal high' mephedrone is even more popular than it was shortly after it was banned by the UK government, according to a survey of London club-goers published in the Journal of Substance Use today.

12 Mar 2012

Thermo Fisher Scientific introduces new ICP-MS system, iCAP Q

Thermo Fisher Scientific Inc., the world leader in serving science, today launched its new Thermo Scientific iCAP Q, an ICP-MS system that features world-class performance and increased throughput to help laboratories cut analysis times by up to 50 percent when compared to the XSERIES 2 ICP-MS, the model it replaces.

From Thermo Fisher Scientific Inc. 12 Mar 2012

Zynex announces acquisition of NeuroDyne Medical

Zynex, Inc., a provider and developer of non-invasive medical devices for electrotherapy and stroke rehabilitation, neurological diagnosis and cardiac monitoring, announced the acquisition of substantially all the assets of NeuroDyne Medical, Corp., through its subsidiary Zynex NeuroDiagnostics, Inc., with an effective date of March 9, 2012.

12 Mar 2012

Connect during MS Awareness Week

Multiple sclerosis is a life altering disease that affects each person in a unique and different way. MS destroys connections, divides minds from bodies, pulls people from their lives and away from one another. Therefore, it's only fitting that connections would be its greatest enemy.

12 Mar 2012

FDA clears Aradigm IND for Pulmaquin Phase 3 clinical trial in non-cystic fibrosis BE

Aradigm Corporation today announced that the Company's Investigational New Drug Application (IND) to conduct a pivotal Phase 3 clinical trial of Pulmaquin (dual release ciprofloxacin for inhalation) in non-cystic fibrosis bronchiectasis (BE) has been cleared by the U.S. Food and Drug Administration.

12 Mar 2012

Korean FDA grants pre-market clearance for ETView's VivaSight‐SL airway management solutions

ETView today announced that the Korean Food and Drug Administration ("KFDA") has granted pre-market clearance for VivaSight‐SL. With KFDA clearance, ETView plans to immediately initiate market launch of VivaSight‐SL. ETView also announced a distribution agreement with ChinooMTech Company.

12 Mar 2012

Antares Pharma fourth quarter revenues increase 65% to $5.4 million

Antares Pharma, Inc. today reported financial and operating results for the fourth quarter and full year ended December 31, 2011 and outlined key objectives and milestones for 2012.

12 Mar 2012

First Edition: March 12, 2012

Today's health policy headlines focus significant attention on key issues, dynamics and even personalities that will be in play when the Supreme Court takes up the health law later this month.

12 Mar 2012

Two scientists receive The Brain Prize 2012 for pioneering work on hearing and deafness

The Grete Lundbeck European Brain Research Foundation announced today that The Brain Prize 2012 is jointly awarded to Christine Petit and Karen Steel.

12 Mar 2012

Interventional Spine's PerX360 System to be presented at ISASS annual meeting

Interventional Spine, Inc. today announced that Dr. Rudolf Morgenstern, Director and Chief Surgeon of the Morgenstern Institute for Endoscopic Spine Surgery at Centro Medico Teknon in Barcelona, and Dr. David Greenwald from Flagler Brain and Spine Institute of St. Augustine, Florida will present the PerX360 System at the International Society for the Advancement of Spine Surgery (ISASS) Annual Meeting in Barcelona, Spain.

12 Mar 2012

Botulinum toxin effective in treating OAB among women

The biggest study into the treatment of urinary incontinence with botulinum toxin (trade name Botox) has demonstrated that it is effective in treating overactive bladder (OAB) - a debilitating common condition which can affect up to 20% of people over the age of 40.

12 Mar 2012